Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.34 |
| ▸ | PTP4A3 | O75365 | 2/20 | 0.32 |
| ▸ | PTP4A1 | Q93096 | 2/20 | 0.32 |
| ▸ | PTP4A2 | Q12974 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7922554 | 0.83 | TDP1 (0.44) | TDP1TSHRCYP3A4MAPTCACNA1B | |
| SCHEMBL10545349 | 0.81 | TDP1 (0.36) | TDP1TSHRCYP3A4 | |
| SCHEMBL476238 | 0.81 | — | — | |
| SCHEMBL7937962 | 0.79 | TDP1 (0.44) | TDP1TSHRCYP3A4MAPTCACNA1B | |
| SCHEMBL5429446 | 0.78 | CYP3A4 (0.35) | TDP1TSHRCYP3A4MAPTCACNA1B | |
| SCHEMBL10966895 | 0.75 | CYP3A4 (0.45) | TDP1TSHRCYP3A4MAPTCACNA1B | |
| SCHEMBL29220272 | 0.75 | TDP1 (0.44) | TDP1TSHRCYP3A4MAPTCACNA1B | |
| SCHEMBL5428036 | 0.75 | TDP1 (0.44) | TDP1TSHRCYP3A4MAPTCACNA1B | |
| SCHEMBL177943 | 0.75 | CYP3A4 (0.48) | TDP1TSHRCYP3A4MAPTCACNA1B | |
| SCHEMBL4675440 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414825-B9 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2009-09-16 | — | — | EP | disclosed |
| US-20080214579-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080153855-A1 | Thieno[2,3-d]pyrimidinedione derivatives; antiproliferative agents against T-cells; chronic obstructive pulmonary disease, asthma; immunosuppressants, antihistamines, bronchodilator agents, and anticarcinogenic agents | ASTRAZENECA AB, A SWEDEN CORPORATION | 2008-06-26 | — | — | US | disclosed |
| US-7384950-B2 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| US-7384951-B2 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| US-7361660-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2008-04-22 | — | — | US | disclosed |
| EP-1414825-B1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| EP-1587812-B1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2006-08-09 | — | — | EP | disclosed |
| EP-1412362-B1 | THIENO¬2,3-d|PYRIMIDINEDIONES AS INHIBITORS OF T-CELLS PROLIFERATION | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| US-20060052400-A1 | Thienopyriminediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1587812-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | AstraZeneca AB (SE) | 2005-10-26 | — | — | EP | disclosed |
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| US-20040171623-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | US | disclosed |
| WO-2004065394-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2004-08-05 | — | — | WO | disclosed |
| EP-1414825-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| EP-1412362-A1 | CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003011868-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003008422-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214579-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | TPMT, TYMP, TYMS | TDP1 128/4885TSHR 822/4885CYP3A4 494/4885 |
| US-20060052400-A1 | Thienopyriminediones and their use in the modulation of autoimmune disease | C5, HRH4, CYP2S1 | TDP1 3314/4885TSHR 76/4885CYP3A4 77/4885 |
| US-20080153855-A1 | Thieno[2,3-d]pyrimidinedione derivatives; antiproliferative agents against T-cells; chronic obstructive pulmonary disease, asthma; immunosuppressants, antihistamines, bronchodilator agents, and anticarcinogenic agents | HRH4, HRH2, HRH3 | TDP1 2157/4885TSHR 281/4885CYP3A4 397/4885 |
| US-20040171623-A1 | Chemical compounds | CBR1, SETDB1, CBR3 | TDP1 1904/4885TSHR 1931/4885CYP3A4 60/4885 |
| US-20040254198-A1 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | TPMT, CBR1, CYP2D6 | TDP1 1899/4885TSHR 293/4885CYP3A4 93/4885 |
| US-20080207642-A1 | Thienopyrimidinediones and Their Use in the Modulation of Autoimmune Disease | C5, TPMT, C9 | TDP1 1544/4885TSHR 178/4885CYP3A4 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.